157 related articles for article (PubMed ID: 35870411)
1. Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature.
Zhang P; Zhu G; Li L; Lai G; Wang Z; Sun C; Xia W; Wu L
Transplant Rev (Orlando); 2022 Dec; 36(4):100712. PubMed ID: 35870411
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.
Kayali S; Pasta A; Plaz Torres MC; Jaffe A; Strazzabosco M; Marenco S; Giannini EG
Liver Int; 2023 Jan; 43(1):8-17. PubMed ID: 36102312
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
Qiu J; Tang W; Du C
Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
[TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
5. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy and transplantation for hepatocellular carcinoma.
Tabrizian P; Abdelrahim M; Schwartz M
J Hepatol; 2024 May; 80(5):822-825. PubMed ID: 38253289
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
Front Immunol; 2021; 12():653437. PubMed ID: 34349755
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
Jiang J; Huang H; Chen R; Lin Y; Ling Q
Front Immunol; 2023; 14():1092401. PubMed ID: 36875077
[TBL] [Abstract][Full Text] [Related]
9. Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.
Ji JH; Ha SY; Lee D; Sankar K; Koltsova EK; Abou-Alfa GK; Yang JD
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108802
[TBL] [Abstract][Full Text] [Related]
10. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
11. An efficient combination immunotherapy for antitumor immunity without accelerating cardiac allograft rejection.
Miao X; Wu Z; Jiang Y; Liu H; Gong W
Immunology; 2023 Jun; 169(2):157-166. PubMed ID: 36517459
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitor Use in Solid Organ Transplant Recipients: A Systematic Review.
Portuguese AJ; Tykodi SS; Blosser CD; Gooley TA; Thompson JA; Hall ET
J Natl Compr Canc Netw; 2022 Apr; 20(4):406-416.e11. PubMed ID: 35390767
[TBL] [Abstract][Full Text] [Related]
13. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.
Abdel-Wahab N; Safa H; Abudayyeh A; Johnson DH; Trinh VA; Zobniw CM; Lin H; Wong MK; Abdelrahim M; Gaber AO; Suarez-Almazor ME; Diab A
J Immunother Cancer; 2019 Apr; 7(1):106. PubMed ID: 30992053
[TBL] [Abstract][Full Text] [Related]
14. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
[TBL] [Abstract][Full Text] [Related]
15. An analysis report on the application of immune checkpoint inhibitors after liver transplantation.
Xie M; Dang ZP; Sun XG; Zhang B; Zhang Q; Tian QJ; Cai JZ; Rao W
Ther Adv Chronic Dis; 2022; 13():20406223221099334. PubMed ID: 35620187
[TBL] [Abstract][Full Text] [Related]
16. Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study.
Guo Z; Liu Y; Ling Q; Xu L; Wang T; Zhu J; Lin Y; Lu X; Qu W; Zhang F; Zhu Z; Zhang J; Jia Z; Zeng P; Wang W; Sun Q; Luo Q; Hu Z; Zheng Z; Jia Y; Li J; Zheng Y; Wang M; Wang S; Han Z; Yu S; Li C; Zhang S; Xiong J; Deng F; Liu Y; Chen H; Wang Y; Li L; Liang W; Schlegel A; Nashan B; Liu C; Zheng S; He X
Am J Transplant; 2024 Apr; ():. PubMed ID: 38642712
[TBL] [Abstract][Full Text] [Related]
17. Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer: A Systematic Review.
Asdourian MS; Shah N; Jacoby TV; Reynolds KL; Chen ST
JAMA Dermatol; 2022 Aug; 158(8):933-941. PubMed ID: 35612829
[TBL] [Abstract][Full Text] [Related]
18. Optimizing the Safe Washout Period for Liver Transplantation Following Immune Checkpoint Inhibitors with Atezolizumab, Nivolumab, or Pembrolizumab.
Kuo FC; Chen CY; Lin NC; Liu C; Hsia CY; Loong CC
Transplant Proc; 2023 May; 55(4):878-883. PubMed ID: 37127513
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.
Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A
Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022
[TBL] [Abstract][Full Text] [Related]
20. Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.
Nguyen LS; Ortuno S; Lebrun-Vignes B; Johnson DB; Moslehi JJ; Hertig A; Salem JE
Eur J Cancer; 2021 May; 148():36-47. PubMed ID: 33721705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]